Medicine for COVID-19: What Are the Treatment Options?

COVID-19 treatment has evolved from a scramble of repurposed drugs into a layered system of antivirals, anti-inflammatory agents, and immune-modulating therapies, each matched to a different stage of illness. For most people catching COVID-19 today, the question is not whether treatments exist but which ones apply to their situation, because the right medicine depends heavily on how sick you are, how long you have been symptomatic, and what other health conditions you carry.

Outpatient Antivirals for Early Illness

If you test positive and are at higher risk of severe disease, the first-line option in most countries is nirmatrelvir/ritonavir, sold under the brand name Paxlovid. This oral antiviral works by blocking an enzyme the virus needs to copy itself. In the pivotal trial of unvaccinated high-risk adults, Paxlovid reduced the rate of hospitalization or death by about 89% compared with placebo when started within three days of symptoms. All 13 deaths in that trial occurred in the placebo group.¹ Timing matters: modeling studies estimate that Paxlovid can reduce viral replication by roughly 91%, but that benefit drops the longer you wait to start treatment.²

One quirk of Paxlovid is “rebound,” where symptoms or viral tests turn positive again a few days after finishing the five-day course. A prospective study found that about 14% of treated patients showed viral rebound and about 19% had symptom rebound, compared with roughly 9% and 7% in untreated controls. Those differences were not statistically significant, meaning rebound can happen without Paxlovid too, but it trends more common with treatment.³ Most rebound episodes are mild and self-limiting, and they do not erase the drug’s benefit in preventing hospitalization.

Paxlovid also comes with a significant practical catch: ritonavir, the booster drug bundled with nirmatrelvir, is a potent inhibitor of liver enzymes that metabolize many common medications. If you take certain blood thinners, heart rhythm drugs, cholesterol-lowering statins, immunosuppressants, or even some over-the-counter supplements processed through the same pathway, you may need dose adjustments or cannot take Paxlovid at all. Your prescriber should review every medication you are on before writing the prescription.

Molnupiravir and Its Mutagenesis Debate

Molnupiravir (brand name Lagevrio) is a second oral antiviral that works through a completely different mechanism. Rather than blocking viral replication outright, it introduces errors into the virus’s genetic code as it copies itself, eventually producing so many mutations that the virus can no longer function.⁴ A meta-analysis of randomized trials confirmed that molnupiravir has a favorable safety profile in terms of common side effects like diarrhea, nausea, and dizziness. But that same mechanism has drawn persistent concern from researchers: if the drug causes lethal mutations in viral RNA, could it also cause mutations in the patient’s own DNA?⁵ This is not a proven harm in clinical trials so far, but the theoretical risk of cancer or birth defects means molnupiravir is generally reserved for situations where Paxlovid cannot be used, and it is not recommended during pregnancy.

There is also a public-health angle to molnupiravir’s mutagenic mechanism: some scientists worry that by pushing the virus to mutate rather than simply killing it, the drug could theoretically encourage the emergence of new variants with unpredictable features.⁴ This remains a subject of active debate rather than settled science.

Remdesivir for Patients Who Can Get an Infusion

Remdesivir (Veklury) was one of the first drugs authorized for COVID-19 and is still used, though its role has narrowed. It is an intravenous antiviral, which limits its convenience. A Cochrane systematic review confirmed that remdesivir prevents the SARS-CoV-2 virus from reproducing and has been approved by multiple regulatory agencies for treating COVID-19.⁶ In practice, remdesivir is used most often when Paxlovid is contraindicated or when a patient needs hospital-level care. A short three-day outpatient IV course has also been studied for high-risk patients early in infection, though the oral options are far more practical for most people.

Dexamethasone and Corticosteroids in the Hospital

Once COVID-19 progresses to the point where you need supplemental oxygen, the disease shifts from being primarily a viral problem to an inflammatory one. The immune system’s overreaction, rather than the virus itself, becomes the main threat. This is where dexamethasone, a cheap and widely available corticosteroid, has saved more lives than perhaps any other COVID-19 therapy.

The landmark RECOVERY trial found that dexamethasone cut deaths by about a third in patients on ventilators and by roughly a fifth in patients receiving oxygen without ventilation.⁷ The drug’s benefit was largest in the sickest patients. Critically, the same trial showed no benefit, and possibly slight harm, in hospitalized patients who did not need oxygen at the time they received dexamethasone. That distinction matters: steroids dampen the immune response, which helps when inflammation is the problem but can be counterproductive when the body still needs its immune system to fight active viral replication. Modeling work estimated that at a population level, dexamethasone can reduce mortality by about 18% in patients needing oxygen and 36% in those on ventilators.⁸

Immunomodulators for Severe and Critical Disease

When steroids alone are not enough, doctors have additional tools to rein in the runaway immune response. Tocilizumab, a drug originally developed for rheumatoid arthritis, blocks a key inflammatory signaling molecule called interleukin-6. Early reports from China showed that in a small group of severe COVID-19 patients, 75% reduced their oxygen needs within five days of receiving tocilizumab, and CT scans showed lung improvement in over 90%.⁹ A larger retrospective study in ICU patients found that those who received tocilizumab had a roughly 36% lower risk of in-hospital death compared with matched patients who did not.¹⁰

Baricitinib, a JAK inhibitor also borrowed from rheumatology, targets a different part of the inflammatory cascade. The large RECOVERY trial found that baricitinib reduced 28-day mortality among hospitalized patients: about 12% of the baricitinib group died compared with 14% in the usual care group.¹¹ A separate meta-analysis of multiple trials confirmed a significant reduction in 28-day mortality and in the combined outcome of disease progression, ventilation, or death.¹² Guidelines generally recommend adding one of these immunomodulators on top of dexamethasone for patients whose oxygen needs are worsening.

Blood Thinners in the Hospital

COVID-19 has a well-documented tendency to cause blood clots, particularly in hospitalized patients. The HEP-COVID trial tested whether therapeutic (full) doses of the blood thinner heparin could reduce clots and deaths compared with the standard preventive dose. Among non-ICU patients, full-dose heparin cut the combined rate of blood clots and death substantially, with rates dropping from about 36% to roughly 17%.¹³ The benefit was not seen in ICU patients, however, and the higher dose does carry an increased risk of major bleeding. The upshot: for moderately ill hospitalized patients with elevated clotting markers, therapeutic heparin can be lifesaving, but the decision requires balancing bleeding risk on a case-by-case basis.

Inhaled Steroids for Outpatients

Inhaled budesonide, the same steroid used in many asthma inhalers, showed early promise for outpatients at risk of complications. The STOIC trial reported that early inhaled budesonide reduced COVID-19-related urgent care visits or hospitalizations by about 91% compared with usual care, with a number needed to treat of just eight.¹⁴ The larger PRINCIPLE trial found that budesonide shortened self-reported recovery by about three days, though its effect on hospitalization fell just short of the pre-set threshold for statistical certainty.¹⁵

A meta-analysis pulling together the trial data confirmed that inhaled budesonide was associated with improved clinical recovery at both 7 and 14 days. Interestingly, a different inhaled steroid, ciclesonide, did not show the same benefit, suggesting this is not simply a class effect of all inhaled corticosteroids.¹⁶ Inhaled budesonide is inexpensive, widely available, and has few side effects, making it a practical add-on for outpatients at higher risk, especially in settings where oral antivirals are unavailable.

Convalescent Plasma

Convalescent plasma, antibody-rich blood products donated by people who have recovered from COVID-19, had a turbulent arc during the pandemic. Early enthusiasm collided with inconsistent trial results, and the therapy largely fell out of routine use. But two specific situations have kept it relevant. A randomized trial in clinically vulnerable patients with mild COVID-19 found that early treatment with very high-titer convalescent plasma prevented all hospitalizations and deaths, compared with about 9% of patients in the standard care group who were hospitalized or died.¹⁷

The other niche is immunocompromised patients with persistent COVID-19 infections that refuse to clear. A case series of six such patients found that combining convalescent plasma with nirmatrelvir/ritonavir appeared effective at resolving the infection, though the authors emphasized that larger trials are needed.¹⁸ The practical challenge is that convalescent plasma must come from donors whose antibodies match currently circulating variants, which makes supply logistics complicated.

Monoclonal Antibodies and the Variant Problem

Monoclonal antibodies were among the highest-profile COVID-19 treatments early in the pandemic. Products like sotrovimab, bebtelovimab, and the combination of tixagevimab and cilgavimab (Evusheld) were designed to neutralize the virus directly. However, SARS-CoV-2 has a moving target of a spike protein, and the Omicron subvariants BA.2, BA.4, and BA.5 showed strong and broad resistance to most of these antibodies.¹⁹

Evusheld had a particularly notable rise and fall. It was authorized as pre-exposure prophylaxis for immunocompromised people who could not mount an adequate vaccine response. A study of over 1,100 severely immunocompromised patients showed that the weekly infection rate among those who received Evusheld was far lower than in the general population of the same region during the same period.²⁰ But as new variants emerged, Evusheld lost its neutralizing activity and its authorization was withdrawn in the United States.²¹ No replacement monoclonal antibody product with reliable activity against current variants is widely available as of now, leaving immunocompromised patients who do not respond to vaccination without a dedicated prevention tool.

Repurposed Drugs That Did Not Work

The pandemic generated enormous interest in repurposing existing drugs, and two became lightning rods for controversy: ivermectin and hydroxychloroquine. Both had plausible-sounding laboratory rationale, and both attracted passionate advocates. The clinical evidence, however, has been consistently negative.

A large randomized trial of ivermectin in outpatients with early COVID-19 found no meaningful difference between the drug and placebo in preventing hospitalization or prolonged emergency department visits.²² A separate randomized trial in hospitalized patients tested both ivermectin and hydroxychloroquine head-to-head against standard care and found that neither reduced hospital stay, respiratory deterioration, or deaths.²³ These results are consistent across numerous trials. No major guideline body recommends either drug for COVID-19.

Vitamin and Mineral Supplements

Vitamin D, zinc, and vitamin C were among the most popular self-prescribed COVID-19 remedies. Their track record in clinical trials has been underwhelming. A double-blind, placebo-controlled trial of vitamin D and zinc supplementation in COVID-19 patients in India found no effect on time to symptom resolution for either supplement.²⁴ A separate randomized trial testing high-dose zinc, high-dose vitamin C, or both in ambulatory COVID-19 patients found no significant difference in symptom duration compared with standard care.²⁵

None of this means these nutrients are useless for overall health. Correcting a genuine deficiency is always reasonable. But expecting vitamin supplements to meaningfully change the course of a COVID-19 infection is not supported by the trial data.

Special Considerations for Immunocompromised and Kidney Disease Patients

People with weakened immune systems, whether from organ transplants, cancer chemotherapy, autoimmune conditions, or HIV, represent a unique treatment challenge. Their infections tend to last longer, respond less reliably to a single antiviral course, and carry higher risk of complications. Research into combination antiviral therapy, using two drugs that target different viral proteins simultaneously, has shown promise for clearing persistent infections. In one study, combined antiviral treatment cleared the virus in 13 of 15 treatment episodes in immunocompromised patients, and no drug-resistance mutations emerged after combination therapy, unlike what was seen with single-drug approaches.²⁶ A European consensus is emerging that combination treatment may be the best strategy for this population.²⁷

Chronic kidney disease adds another layer of complexity. Most antiviral trial populations excluded patients with impaired kidney function, leaving doctors to extrapolate doses and monitor for toxicity. A review in Frontiers in Pharmacology discussed the pharmacokinetics of remdesivir, Paxlovid, molnupiravir, and other antivirals in patients with various stages of kidney disease, emphasizing the need for dose adjustments and close monitoring of side effects.²⁸ If you have kidney disease, make sure your prescriber is aware before starting any COVID-19 antiviral.

Treatment for Long COVID

The search for effective long COVID treatments is still in its early stages, and the honest assessment is that nothing has yet been proven to reliably reverse the condition. A systematic review of the global trial landscape identified 312 clinical studies testing potential long COVID therapies, spanning physical exercise, rehabilitation, behavioral therapy, and drugs including Paxlovid and fluvoxamine. Most were conducted in the United States, India, and Spain. Only 11 of those studies had published results at the time of the review, and those results were not encouraging.²⁹

A narrative review of expert and patient-driven treatment priorities found that only six of 14 prioritized interventions had long-COVID-specific randomized trial evidence. Exercise had the most data behind it, with 16 trials, while antivirals, vagus nerve stimulation, and monoclonal antibodies each had just one or two small trials. The rest relied on indirect evidence or mechanistic reasoning.³⁰ A separate systematic review identified rintatolimod as having modest-to-high potential for the fatigue-dominant subtype, LTY-100 and Treamid for lung fibrosis, and metformin for general long COVID prevention, but cautioned that most investigational drugs showed limited promise.³¹

A major challenge is that long COVID appears to have multiple subtypes with distinct underlying mechanisms, meaning a single treatment is unlikely to help everyone. The research is moving toward tailored approaches, but for now, management remains largely symptomatic: pacing, targeted rehabilitation, and treating individual symptoms like pain, sleep disruption, or mood disorders as they arise.

The Guideline Landscape After the Emergency

During the pandemic, the NIH maintained a living treatment guideline that was continuously updated as new evidence emerged. With the end of the public health emergency, those guidelines were retired. Responsibility for maintaining COVID-19 treatment recommendations has shifted to professional medical societies like the Infectious Diseases Society of America, the American College of Physicians, the Pediatric Infectious Diseases Society, and the World Health Organization.³² This decentralization means that treatment recommendations may vary slightly depending on which guideline your doctor follows, though the core evidence base is the same.

Access and Equity Worldwide

Having effective treatments means little if they cannot reach the people who need them. Pfizer and the Medicines Patent Pool agreed to allow 95 low- and middle-income countries to access affordable generic versions of Paxlovid. But those generics have been delayed by the need for bioequivalence testing, and many of the countries covered by the deal account for only a small fraction of global COVID-19 diagnoses. Meanwhile, about 39% of diagnosed cases come from middle-income countries that were excluded from the deal, forcing them to pay higher prices.³³ Testing capacity itself is a bottleneck: you cannot prescribe a five-day antiviral course if patients are not diagnosed within the first five days of illness. For much of the world, the practical treatment for mild COVID-19 remains rest, hydration, and over-the-counter symptom relief, not because better options do not exist, but because they are out of reach.

Nasal Antivirals and Next-Generation Approaches

Looking beyond the current toolkit, researchers are exploring antivirals that could be delivered as nasal sprays, potentially blocking the virus at the point of entry. One experimental approach uses a positively charged polymer called GCPQ that binds electrostatically to SARS-CoV-2, preventing viral entry into host cells. In laboratory studies, it reduced viral infectivity by a factor of 1,000 to 10,000, and in mouse models it showed a trend toward reducing viral load in the respiratory tract, though the animal study was too small to confirm statistical significance. The polymer lingered in mouse nasal passages for at least 24 hours after dosing, suggesting potential as a prophylactic.²⁶ This kind of approach is still preclinical, but it represents a conceptually different strategy: rather than treating infection after it takes hold, a nasal spray could be used before exposure, much like sunscreen for the respiratory tract. Researchers have also proposed adapting the pre-exposure prophylaxis model used in HIV prevention to SARS-CoV-2, using antiviral and adjuvant drugs to protect healthcare workers, immunocompromised individuals, and poor vaccine responders.³⁴ Whether these concepts move from proposal to pharmacy shelves depends on clinical trial results that are still years away.

1
PubMed Central. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
2
PubMed Central. A retrospective cohort study of Paxlovid efficacy depending on treatment time in hospitalized COVID-19 patients
3
Clinical Infectious Diseases. The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls
4
PubMed. A tale of two drugs: Molnupiravir and Paxlovid
5
PubMed Central. Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
6
PubMed Central. Remdesivir for the treatment of COVID‐19
7
PubMed. Dexamethasone in Hospitalized Patients with Covid-19
8
Nature Communications. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19
9
PubMed Central. Effective treatment of severe COVID-19 patients with tocilizumab
10
The Lancet Rheumatology. Tocilizumab in patients hospitalised with COVID-19 requiring intensive care unit support: a retrospective observational cohort study
11
The Lancet. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
12
PubMed Central. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials
13
JAMA Internal Medicine. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19
14
The Lancet Respiratory Medicine. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
15
PubMed Central. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
16
PLOS ONE. Clinical efficacy of inhaled corticosteroids in patients with coronavirus disease 2019: A living review and meta-analysis
17
eBioMedicine. Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): a randomised, controlled, open-label trial
18
PubMed Central. High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
19
Nature Reviews Microbiology. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
20
PubMed Central. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
21
EClinicalMedicine. Medicine for COVID-19: What Are the Treatment Options?
22
PubMed. Effect of Early Treatment with Ivermectin among Patients with Covid-19
23
PubMed Central. Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial
24
PubMed Central. Vitamin D and Zinc Supplementation to Improve Treatment Outcomes among COVID-19 Patients in India: Results from a Double-Blind Randomized Placebo-Controlled Trial
25
JAMA Network Open. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection
26
Scientific Reports. Evaluation of the efficiency of combined antiviral therapy in COVID-19 challenging immunocompromised patients
27
PubMed Central. Antiviral Combination Treatment for COVID-19 in Immunocompromised Patients: Towards Defining Its Place in Therapy
28
PubMed Central. How to use COVID-19 antiviral drugs in patients with chronic kidney disease
29
PubMed. The global clinical studies of long COVID
30
PubMed Central. Candidate treatments for long COVID: a narrative review of expert and patient-driven priorities
31
PubMed. Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review
32
PubMed. National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned
33
PubMed Central. Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19
34
PubMed Central. SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders